Cardiopulmonary exercise testing and six-minute walk correlations in pulmonary arterial hypertension.

[1]  K. Wasserman,et al.  Clinical efficacy of sildenafil in primary pulmonary hypertension. , 2004, Journal of the American College of Cardiology.

[2]  B. Khandheria,et al.  Working group 6: The role of technology to enhance clinical and educational efficiency. , 2004, Journal of the American College of Cardiology.

[3]  A. Torbicki,et al.  End points and clinical trial designs in pulmonary arterial hypertension: clinical and regulatory perspectives. , 2004, Journal of the American College of Cardiology.

[4]  B. Raju,et al.  Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. , 2004, Journal of the American College of Cardiology.

[5]  R. Dixon,et al.  Sitaxsentan therapy for pulmonary arterial hypertension. , 2004, American journal of respiratory and critical care medicine.

[6]  Grace Wu,et al.  The 6-minute walk test: how important is the learning effect? , 2003, American heart journal.

[7]  K. Wasserman,et al.  Beraprost therapy for pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[8]  W. Seeger,et al.  Inhaled iloprost for severe pulmonary hypertension. , 2002, The New England journal of medicine.

[9]  W. Seeger,et al.  Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. , 2002, American heart journal.

[10]  M. Humbert,et al.  Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. , 2002, Journal of the American College of Cardiology.

[11]  R. Barst,et al.  Bosentan therapy for pulmonary arterial hypertension. , 2002, The New England journal of medicine.

[12]  S. Rich,et al.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. , 2002, American journal of respiratory and critical care medicine.

[13]  D. Badesch,et al.  Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled study , 2001, The Lancet.

[14]  J. E. Hansen,et al.  Exercise Pathophysiology in Patients With Primary Pulmonary Hypertension , 2001, Circulation.

[15]  K. Wasserman,et al.  The body weight-walking distance product as related to lung function, anaerobic threshold and peak VO2 in COPD patients. , 2001, Respiratory medicine.

[16]  M. Rubenfire,et al.  Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. , 2001, The European respiratory journal.

[17]  M. Fujita,et al.  Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. , 2000, American journal of respiratory and critical care medicine.

[18]  D. Rubin,et al.  Comparing Correlated but Nonoverlapping Correlations , 1996 .

[19]  Xiao-Li Meng,et al.  Comparing correlated correlation coefficients , 1992 .

[20]  G. Guyatt,et al.  The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. , 1985, Canadian Medical Association journal.